Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price83.62 USD
Fair value83.16
Ethical score70.0/100
Our investment reviews on this name
2026-08-22Read Distribution88.80-5.8% to today ✓
2026-07-02Read Markup82.50+1.4% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Anterix Inc. holds its Distribution at $83.62. The statistical read favours the sellers, held for 10 days.
As held on the ledger · 2026-09-21
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 10 days
Price at the screen
$83.62
Valuation
23.96 trailing · 40.59 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.84
The Workings
Five Screens, Shown in Full
Does not pass. Revenue purity
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.95%
Below 33%
Interest-bearing debt is just 0.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
23.47%
Below 49%
Money owed to the company is 23.5% of assets, under the 49% limit.
Pass
Revenue purity
25.12%
Below 5%
25.1% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. The price runs 0.6% above the base estimate.
Third-party analyst targets: 3 covering, consensus None. The average target sits +45% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ATEX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 11.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 117% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 133%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $55.
2026-07-22Markup$100.35+21.6%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 21.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 117% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 133%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $55.
2026-07-18Markup$82.50+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 117% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 133%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $55.
2026-07-03Markup$82.50+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$82.50Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
